Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
Compositions comprising derivatives of biopterin, useful for the treatment of traumatic brain injury, non-traumatic brain injury, elevated cranial pressure, and secondary brain injury.
1. A method of treating a disease in a subject, comprising the step of administering to a subject in need thereof a solid pharmaceutical composition comprising
a) a compound having the formula (I):
and/or a compound having the formula (II):
and
b) two different sodium phosphate salts, wherein the two different sodium phosphate salts are NaH 2 PO 4 .2H 2 O and Na 2 HPO 4 .2H 2 O, and wherein the quantity of the NaH 2 PO 4 .2H 2 O and Na 2 HPO 4 .2H 2 O present in the composition is chosen such that the molar ratio of both NaH 2 PO 4 .2H 2 O and Na 2 HPO 4 .2H 2 O to compound (I) or compound (II) ranges from 0.02 to 0.5, with the proviso that the composition does not include an antioxidant,
wherein the disease is selected from the group consisting of traumatic brain injury, non-traumatic brain injury, elevated cranial pressure, and secondary brain injury.
2. The method of claim 1 , wherein the compound (I) and/or the compound (II) are present as the free base.
3. The method of claim 1 , wherein the pharmaceutical composition comprises an additional pharmaceutical excipient.
4. The method of claim 3 , wherein the additional pharmaceutical excipient is an inorganic salt.
5. The method of claim 4 , wherein the inorganic salt is NaCl.
6. The method of claim 1 , wherein the composition further comprises crystallization water.
7. The method of claim 1 , wherein a unit dosage of the composition contains 650±60 mg of the free base of 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or of 4-Amino-7,8-dihydro-L-biopterin, 140±30 mg of water of crystallization, 70±7 mg Na 2 HPO 4 .2H 2 O, 16.5±2 mg NaH 2 PO 4 .2H 2 O, and 350±30 mg NaCl.
8. The method of claim 1 , wherein the non-traumatic brain injury is stroke or meningitis.
9. The method of claim 1 , wherein the pharmaceutical composition is a lyophilized pharmaceutical composition.
10. The method of claim 1 , wherein the compound having the formula (I) or formula (II) is administered at a maximal daily dose selected from the group consisting of about 10 mg/kg body weight, about 8.5 mg/kg body weight, about 7.5 mg/kg body weight, about 5.0 mg/kg body weight, and about 2.5 mg/kg body weight.
11. The method of claim 10 , wherein the injectable solution is administered to the subject by infusion or injection.
12. The method of claim 11 , comprising reconstituting the lyophilized pharmaceutical composition in a pharmaceutically acceptable fluid to form an injectable solution.
13. The method of claim 1 , wherein the compound (I) is (6R)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin.
14. The method of claim 1 , wherein the compound (I) is (6S)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin.
15. The method of claim 1 , wherein the compound (I) is a diastereomeric mixture that comprises more (6R)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin than (6S)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin.
16. The method of claim 15 , wherein the quantity of the (6R)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin and the (6S)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin is chosen such that the ratio of the amount of (6R)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin to the (6S)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin ranges from 1.1 to 2.
17. The method of claim 1 , wherein the subject is a human.